Name:
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial
Description:
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/ea8061b5-efea-4552-a8c8-335235bffe8e/videoscrubberimages/Scrubber_34.jpg
Duration:
T00H01M42S
Embed URL:
https://stream.cadmore.media/player/ea8061b5-efea-4552-a8c8-335235bffe8e
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/ea8061b5-efea-4552-a8c8-335235bffe8e/FSG - ARASENS - Animation V5.mp4?sv=2019-02-02&sr=c&sig=PcJt16gssrt6V0YFTZTnSfkX2bGy%2Fpfsc8vQeoUaeXs%3D&st=2024-11-21T14%3A34%3A10Z&se=2024-11-21T16%3A39%3A10Z&sp=r
Upload Date:
2022-06-27T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
PRESENTER: The phase 3 ARASENS study involved participants diagnosed with metastatic hormone-sensitive prostate cancer, a cancer that spread beyond the prostate to other parts of the body and can be treated with hormone therapy. Researchers aimed to discover if darolutamide could help people with this cancer live longer. In addition to androgen deprivation therapy or ADT, a hormone therapy, and docetaxel, a type of chemotherapy.
PRESENTER: One group received darolutamide. The other group received placebo. Results showed darolutamide improved participants' ability to live longer. In the darolutamide group, it took longer for participants' cancer to become castration-resistant when it no longer responds to hormone therapy. Symptoms including worsening pain, cancer-related bone fractures, and the need for additional medication for cancer were delayed in the darolutamide group compared to the placebo group.
PRESENTER: The percentages of participants who experienced side effects were similar between both groups. Members of the prostate cancer community gave their perspectives on what the results of the ARASENS study mean to them. The results support the use of darolutamide in combination with ADT and docetaxel as an effective well-tolerated treatment option, setting a new standard of care for patients with metastatic hormone-sensitive prostate cancer.
PRESENTER:
